Y-Axis Jobs Logo
Send us feedback
telephone  +91 7670 800 001
Log in Sign up Try Premium
FAP-based Targeted Radionuclides as Immune Modulators in Ovarian and Breast at centredtud
, , Belgium -
Full Time

Start Date

Immediate

Expiry Date

21 Mar, 26

Salary

0.0

Posted On

21 Dec, 25

Experience

2 year(s) or above

Remote Job

Yes

Telecommute

Yes

Sponsor Visa

No

Skills

Targeted Radionuclide Therapy, Immunomodulatory Effects, Tumor Microenvironment, Ovarian Cancer, Triple-Negative Breast Cancer, FAP-Targeted TRT, Immune Checkpoint Inhibitors, Preclinical Studies, Biodistribution, Immune Activation, Tumor Response, Radiopharmaceutical Science, Translational Oncology, Combination Therapy, Cytotoxic Effects, High-Efficacy Treatment

Industry

Research Services

Description
Targeted radionuclide therapy (TRT) is emerging as a transformative approach in oncology, offering both cytotoxic and immunomodulatory effects within the tumor microenvironment (TME). This project explores FAP-targeted TRT as a strategy to overcome immune resistance in ovarian cancer (OC) and triple-negative breast cancer (TNBC), two aggressive, treatment-resistant cancers with high unmet clinical needs. By directing ionizing radiation to FAP-expressing cancer-associated fibroblasts, TRT aims to disrupt the immunosuppressive TME and enhance immune infiltration. The research will investigate the therapeutic synergy between FAP-based TRT and immune checkpoint inhibitors (ICIs), focusing on β-emitters (177Lu, 161Tb) and α-emitters (225Ac). Through preclinical studies in syngeneic and oncogenic murine models, the project will assess biodistribution, immune activation, and tumor response. Key objectives include characterizing immune modulation, optimizing treatment regimens, and evaluating radiobiological mechanisms. By integrating radiopharmaceutical science, immunotherapy, and translational oncology, this project aims to develop a robust combination therapy platform for OC and TNBC which can help bring it toward clinical application, offering a novel, high-efficacy treatment strategy for aggressive female cancers.
Responsibilities
The project will explore FAP-targeted TRT to enhance immune infiltration and disrupt the immunosuppressive tumor microenvironment. It will assess therapeutic synergy with immune checkpoint inhibitors through preclinical studies.